Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118962 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy
A Phase 2 study of Epilepsy, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 19
- Study locations
NCT01118962 is a Phase 2 study of Epilepsy that has completed, run by UCB Biosciences. The registered enrollment target is 39 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The trial reports 19 study locations across 18 states.
The verdict
NCT01118962, a Phase 2 study of Epilepsy, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 19
- Study locations
Study Summary
The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy. Additionally, to allow subjects who have completed SP0961 (NCT01118949) to continue to receive Lacosamide.
Conditions Studied
Interventions
- DRUG Lacosamide
Study Locations (19)
Kentucky
- 605 - Lexington
- 616 - Louisville
Arizona
- 603 - Phoenix
Arkansas
- 602 - Little Rock
Colorado
- 628 - Aurora
Georgia
- 613 - Atlanta
Idaho
- 617 - Boise
Indiana
- 614 - Fort Wayne
Maine
- 619 - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118962
The ClinicalTrials.gov registry entry for NCT01118962 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (96% lower). The listed sponsor is UCB Biosciences, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Lacosamide is the first listed.
NCT01118962 reports 19 study locations spanning 18 distinct geographic areas - top geographies include Kentucky, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT01118962 about?
NCT01118962 is a clinical study titled "Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy". The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy. Additionally, to allow subjects who have completed SP0961 (NCT01118949) to c...
What is the current status of trial NCT01118962?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2010-08. Estimated completion is 2012-10.
What conditions does trial NCT01118962 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT01118962?
The interventions under investigation include: Lacosamide (DRUG).
Who is sponsoring clinical trial NCT01118962?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01118962 being conducted?
This trial has 19 study locations across Arizona, Arkansas, Colorado, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.